ACHRI study finds CellCept® improves survival in pediatric heart transplant patients

April 11, 2005

Little Rock, AR and Philadelphia, PA, April 9, 2005 - Pediatric heart transplant recipients taking the medication CellCept® (mycophenolate mofetil) as part of their anti-rejection treatment regimen experienced significantly fewer early rejection episodes and greatly improved survival, according to a study of nearly 400 pediatric patients, beginning two weeks post-transplant. The study was led by researchers at the Arkansas Children's Research Institute (ACHRI) and results were presented today at the 25th annual meeting of the International Society for Heart and Lung Transplantation in Philadelphia.

"With pediatric heart transplant recipients, it is especially important to focus on long-term transplant success," explained Dr. W. Robert Morrow, chief of pediatric cardiology at Arkansas Children's Hospital (ACH) and the Department of Pediatrics in the University of Arkansas for Medical Sciences College of Medicine, lead investigator of the study. "Our research shows that we can achieve very high survival rates by using therapies such as CellCept in our pediatric transplant recipients."

More than 26,000 American children have received an organ transplant. However, organ rejection remains one of the leading causes of death in transplant recipients, with only half of recipients living longer than nine years.

Morrow and his colleagues in the Pediatric Heart Transplant Study Group compared the incidence of rejection and survival in 395 pediatric patients surviving greater than two weeks post-transplant, ranging in age from one day to 17.9 years, with initial immunosuppression of cyclosporine and either CellCept or azathioprine (AZA). They found that freedom from rejection after 12 months was 10 percent higher with those treated with CellCept (63% of CellCept patients versus 53% of AZA patients). The study also determined that the one-year survival rate was significantly better in CellCept patients (96%), compared to only 87% of the AZA patients.

"It's reassuring to see that, based on this research, the benefits of this therapy for adults are also applicable to pediatric patients," said Dr. Morrow.

Under Dr. Morrow's direction as chief of cardiology since 1996, the pediatric heart transplant program at ACH has consistently been recognized as one of the top programs in the nation. In 1999, the program was named one of the 10 best in the nation by the U.S. Department of Health and Human Services in the vital areas of one-year survival rate and speed of transplant receipt. In 2001, ACH became the only children's hospital in the nation approved as a Medicare cardiac transplant center and one of only three approved by the BlueCross BlueShield Association.

Ketchum UK

Related Pediatric Patients Articles from Brightsurf:

Pediatric surgeon establishes first-ever guidelines for pediatric opioid prescribing
In addition to adults, opioid addiction and misuse affects the pediatric population.

Small study shows convalescent plasma is safe to use in pediatric patients with COVID-19
Early findings from researchers at Children's Hospital of Philadelphia (CHOP) show that convalescent plasma appears to be a safe and possibly effective treatment for children with life-threatening cases of COVID-19.

How COVID-19 affects pediatric patients
New insights into the clinical and epidemiological characteristics of pediatric patients with coronavirus disease 2019 (COVID-19) could facilitate early identification and intervention in suspected patients, according to a study publishing on June 16, 2020 in the open-access journal PLOS Medicine by Xihui Zhou of the First Affiliated Hospital of Xi'an Jiaotong University, China and colleagues.

COVID-19 associated with dramatic decline in ED use by pediatric asthma patients
The number of patients visiting the emergency department (ED) for asthma treatment dropped by 76% in the first month of the COVID-19 pandemic, according to a new study by researchers at Children's Hospital of Philadelphia (CHOP).

Telemedicine effective for monitoring patients in large pediatric neurology network
As the COVID-19 pandemic sent entire communities into lockdown, doctors quickly adopted telehealth strategies without knowing whether they would be effective or feasible.

COVID-19 in pediatric surgical patients at 3 US children's hospitals
This study assessed how many pediatric patients presenting for surgery at three tertiary care children's hospitals across the US had COVID-19.

Clinical, immune features of hospitalized pediatric patients with COVID-19
The immunologic features of mild and moderate COVID-19 in pediatric patients is described and compared in this case series.

Study examines why colon cancer is more deadly in pediatric and young adult patients
Colon cancer is more likely to be lethal in children and young adults than middle-aged adults.

Getting to the heart of epinephrine use in pediatric cardiac arrest patients
The effectiveness of epinephrine treatment during resuscitation of adult patients with cardiac arrest is generally promising, but little is known about its effects in pediatric patients.

High rates of vaccine-preventable infections in pediatric transplant patients
University of Colorado researchers have found lower vaccination rates among children who receive liver transplants, increasing the risk of sickness for those children, who already face significant health issues.

Read More: Pediatric Patients News and Pediatric Patients Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to